Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema

Sponsor
King Khaled Eye Specialist Hospital
Study ID
NCT02096874
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month

Study Details

Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.

Key Dates

First listed
Mar 26, 2014
Start date
Jun 30, 2013
Status verified
Dec 2021
Primary completion
Dec 31, 2014
Completion
Jun 30, 2015

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Bevacizumab
    Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.

Primary Outcome Measure

Peripheral retinal ischemia [ Time Frame: 24 weeks ]

Related Studies